"Bioengineering of Direct Cellular Reprogramming"
Spring 2016 Colloquium Series
|Speaker: Kam W. Leong
Department of Biomedical Engineering
Abstract: Direct cell reprogramming, where differentiated cells are reprogrammed into another lineage without going through an intermediate stem cell-like stage, produces cells promising for regenerative medicine. It obviates the use of embryos and minimizes the risk of teratoma formation associated with the use of induced pluripotent stem cells. To facilitate eventual translation of transdifferentiation technologies we have demonstrated the feasibility of converting fibroblasts into neurons by nonviral overexpression of transcription factors. The poor conversion efficiency of nonviral direct cell reprogramming requires improvement. I will discuss our effort on using engineering strategies to optimize the biochemical and physical cues to enhance direct cell reprogramming. I will present our recent work on converting human endothelial progenitors to smooth muscle cells and also discuss the approach on using CRISPR/dCas9 gene activation approach to achieve direct cellular reprogramming.
Kam W. Leong is the Samuel Y. Sheng Professor of Biomedical Engineering at Columbia University. He received his PhD in Chemical Engineering from the University of Pennsylvania. After serving as a faculty in the Department of Biomedical Engineering at The Johns Hopkins School of Medicine for almost 20 years, he moved to Duke University in 2006 to focus on understanding and exploiting the interactions of cells with nanostructures for therapeutic applications. After moving to Columbia University in September 2014, he continues to work on nanoparticle-mediated nonviral gene delivery and immunotherapy, from design and synthesis of new carriers to applications for hemophilia and infectious diseases. The lab also works on the application of nanostructured biomaterials for regenerative medicine, particularly on understanding cell-topography interactions and on the application of nonviral vectors for direct cellular reprogramming. He has published ~300 peer-reviewed research manuscripts with citations exceeding 30,000, and holds more than 50 issued patents. His work has been recognized by a Young Investigator Research Achievement Award of the Controlled Release Society, Distinguished Scientist Award of the International Journal of Nanomedicine, and Clemson Award for Applied Research of the Society for Biomaterials. He is the Editor-in-Chief of Biomaterials, a member of the National Academy of Inventors, and a member of the USA National Academy of Engineering.
|Host: Professor Ki Bum Lee|
|~ Coffee/tea will be served prior to lecture ~|